RZLT Projected Dividend Yield
Rezolute Inc ( NASDAQ : RZLT )Rezolute is a clinical-stage biopharmaceutical company developing therapies for metabolic diseases related to chronic glucose imbalance. Co.'s primary clinical asset, RZ358, is a potential treatment for congenital hyperinsulinism, a pediatric genetic disorder characterized by excessive production of insulin by the pancreas. Co.'s second clinical asset, RZ402, is an oral plasma kallikrein inhibitor being developed as a potential therapy for the chronic treatment of diabetic macular edema. 21 YEAR PERFORMANCE RESULTS |
RZLT Dividend History Detail RZLT Dividend News RZLT Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |